Integrating Xpert MTB/RIF for TB diagnosis in the private sector: evidence from large-scale pilots in Patna and Mumbai, India

BACKGROUND: Xpert MTB/RIF (Xpert) has been recommended by WHO as the initial diagnostic test for TB and rifampicin-resistance detection. Existing evidence regarding its uptake is limited to public health systems and corresponding resource and infrastructure challenges. It cannot be readily extended...

Descripción completa

Detalles Bibliográficos
Autores principales: Deo, Sarang, Jindal, Pankaj, Papineni, Sirisha
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7844908/
https://www.ncbi.nlm.nih.gov/pubmed/33509114
http://dx.doi.org/10.1186/s12879-021-05817-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7844908/
https://www.ncbi.nlm.nih.gov/pubmed/33509114
http://dx.doi.org/10.1186/s12879-021-05817-1

Ejemplares similares